Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: Louise, a black English Labrador, doesn't ask anything of Casteel except to provide a warm lap to sit in or a ball to chase across the room. For Casteel, it's about the best therapy she's ever had. (Louise) calms me down," said Casteel, who lives in the Manhattan area. "She'll play with you, she'll sit with you. She knows when you're sad." Casteel is a client at Veridian Behavioral Health, a multi-disciplinary mental health care center that is part of the behavioral health department of Salina Regional Health Center. Many of Veridian's psychiatrists, counselors and nurse practitioners serve individuals and families struggling with common life problems such as depression, anxiety, PTSD, marital problems, parent-child conflicts or grief and loss. Recently, the center added another tool to help clients in their programs certified therapy dogs. Three dogs specifically, have been introduced to the programs: Louise, a Chesapeake Bay retriever named Phil and a Great Dane named Daisy. These dogs assist adult inpatient and outpatient clients at the hospital, as well as children suffering trauma and other mental health issues at Veridian's east campus, the Salina Journal reported. Angela Koerperich, an advanced nurse practitioner who owns and supervises Daisy, said Veridian received a grant in October 2015 to add three certified therapy dogs into its mental health program. She and two other Veridian nurse practitioners took on a dog: Louise belongs to Jennifer Pekarek and Phil is owned by Marcia Cleavenger. "We've talked about this for years as something that would be great to have in the inpatient unit," Koerperich said. "We worked together to make it happen. We got in contact with CARES, and the pieces just came together." CARES, which stands for Canine Assistance Rehabilitation Education & Services, is Concordia-based specialty service that offers specially trained canine assistants to people with disabilities throughout the U.S., as well as professional therapy dogs for schools, mental health facilities, hospitals and nursing homes. The majority of dogs that CARES trains are produced from their own breeding programs or are donated ex-show dogs, specifically bred puppies and family pets. Dogs are fostered out to volunteer homes and facilities where they are raised for nine to 18 months, learn basic obedience and become socialized to all aspects of public and private life. Louise and Daisy happened to be trained by inmates at the Ellsworth Correctional Facility, Cleavenger said, which has established a dog training program. "It can be nearly a two year process before they're certified," she said. To become a certified therapy animal, a dog has to have the right kind of temperament to interact with subjects who may be going through trauma or other mental or physical issues, Cleavenger said. "A lot of times people come into the clinic, and they'll be highly anxious or depressed," she said. "A therapy dog helps to ease the anxiety and make it easier to converse with that person. I've had a patient with high blood pressure who, once they spent a little time with Phil, their high blood pressure dropped." Koerperich said Daisy, who like the other therapy dogs wears an identifiable vest while at "work," does wonders with children at the Veridian outpatient office. "Sometimes it's hard to get children to engage or take their medicine, and the dogs can help," she said. "When you are talking to kids about trauma, it's nice to have Daisy in the room. Sometimes a child will talk to the dog and not the therapist. They'll take Daisy outside, walk her around. It's nice to have that physical distraction." Pekarek said at Veridian's inpatient unit at the hospital, Louise has been an immense help when it comes to communicating with patients who are virtually disabled as a result of trauma or mental issues. "Louise seems to warm up to people really fast," Pekarek said. "I'll bring Louise into the inpatient units, and she seems to know who needs her the most. She will stay with them, even if that person won't get out of bed. There was 14-year-old girl here who would not talk to me or her mother, but she talked to Louise. It's amazing to watch." For Casteel, having Louise by her side during therapy sessions has given her hope that her life will continue to improve in the future. "I got an animal myself after I met Louise," she said. "I know now that I need an emotional support animal, that without one I'll be more depressed than usual. I got a cat, but he's as gentle as (Louise) is." ___ Information from: The Salina (Kan.) Journal, http://www.salina.com Claim: Salina center's therapy dogs help manage mental health.
[A]: Whenever Jackie Casteel has difficulty dealing with her depression and post-traumatic stress disorder, she knows she can rely on the comforting paw of a four-legged therapist named Louise.

[Q]: Paragraph: Cancer patients increasingly are having their care guided by gene tumor boards, a new version of the hospital panels that traditionally decided whether surgery, radiation or chemotherapy would be best. These experts study the patient's cancer genes and match treatments to mutations that seem to drive the disease. "We dissect the patient's tumor with what I call the molecular microscope," said Dr. Razelle Kurzrock, who started a board at the University of California, San Diego, where Cairnes is treated. It's the kind of care many experts say we should aim for precision medicine, the right drug for the right person at the right time, guided by genes. There are success stories, but also some failures and many questions: Will gene-guided care improve survival? Does it save money or cost more? What kind of gene testing is best, and who should get it? "I think every patient needs it," especially if cancer is advanced, said Kurzrock, who consults for some gene-medicine companies. "Most people don't agree with me yet. In five years, it may be malpractice not to do genomics." Few people get precision medicine today, said Dr. Eric Topol, head of the Scripps Translational Science Institute. "The only thing that's gone mainstream are the words." HOW IT WORKS NOW If you have a cancer that might be susceptible to a gene-targeting drug, you may be tested for mutations in that gene, such as HER2 for breast cancer. Some breast or prostate cancer patients also might get a multi-gene test to gauge how aggressive treatment should be. Then most patients get usual guideline-based treatments. If there's no clear choice, or if the disease has spread or comes back, doctors may suggest tumor profiling comprehensive tests to see what mutations dominate. That's traditionally been done from a tissue sample, but newer tests that detect tumor DNA in blood liquid biopsies are making profiling more common. The tests cost about $6,000 and many insurers consider them experimental and won't pay. Gene tumor boards analyze what the results suggest about treatment. They focus on oddball cases like a breast cancer mutation in a colon cancer patient, or cancers that have widely spread and are genetically complex. The only options may be experimental drugs or "off-label" treatments medicines approved for different situations. But as tumor profiling grows, it's revealing how genetically diverse many tumors are, and that oddball cases are not so rare, said Dr. John Marshall. He heads the virtual tumor board at Georgetown Lombardi Comprehensive Cancer Center that also serves cancer centers in Pennsylvania, North Carolina, Michigan and Tennessee. "There is a little bit of faith" that testing will show the right treatment, but it's not a sure thing, said Dr. Lee Schwartzberg, who heads one participating center, the West Cancer Center in Memphis. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, is optimistic yet wary. Drugs that target BRAF mutations work well for skin cancers called melanomas, but less well for lung or colon cancers. "Just because a mutation occurs it doesn't mean that drug is going to work in that cancer," he said. LUCKY CASES When it does, results can be dramatic. Cairnes' cancer was between her stomach and esophagus, and had spread to her liver, lungs and lymph nodes. Tissue testing found 10 abnormal genes, but on the liquid biopsy only EGFR popped out as a good target. Two drugs aim at that gene but aren't approved for her type of cancer. A tumor board advised trying both Erbitux and Tarceva, the drug her husband also had taken. Within two weeks, she quit using pain medicines. After two months, her liver tumor had shrunk roughly by half. There are signs that cancer may remain, but it is under control. She feels well enough to travel and to take care of her granddaughter. "I'm very, very grateful to have a targeted therapy," Cairnes said. "I cannot expect a better outcome than what we're seeing right now," said her doctor, Shumei Kato. WHAT STUDIES SHOW But is gene-guided treatment better than usual care? French doctors did the first big test, with disappointing results. About 200 patients with advanced cancer were given whatever their doctors thought best or off-label drugs based on tumor profiling. Survival was similar about two months. Another French study, reported in June, was slightly more encouraging on survival but exposed another problem: No drugs exist for many gene flaws. Tests found treatable mutations in half of the 2,000 participants and only 143 got what a tumor board suggested. Some doctors worry that tumor boards' recommending off-label treatments diverts patients from research that would benefit all cancer patients. For example, the American Society of Clinical Oncology's TAPUR study tests off-label drugs and shares results with their makers and federal regulators. LETTING PATIENTS CHOOSE Ann Meffert, who lives on a dairy farm in Waunakee, Wisconsin, endured multiple standard treatments that didn't defeat her bile duct cancer. "She was going to be referred to hospice; there was not much we could do," said Dr. Nataliya Uboha, who took the case to a tumor board at the University of Wisconsin-Madison. The panel gave several options, including off-label treatment, and Meffert chose a study that matches patients to gene-targeting therapies and started on an experimental one last October. "Two weeks in, I started feeling better," she said, and when she saw test results, "I couldn't believe the difference." Many lung spots disappeared and the liver tumor shrank 75 percent. She is not cured, though, and doctors are thinking about next steps. And that could involve a fresh look at her tumor genes. ___ Marilynn Marchione can be followed at @MMarchioneAP __ This Associated Press series was produced in partnership with the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content. Claim: Ultra-personal therapy: Gene tumor boards guide cancer care.
[A]: Doctors were just guessing a decade ago when they gave Alison Cairnes' husband a new drug they hoped would shrink his lung tumors. Now she takes it, but the choice was no guesswork. Sophisticated gene tests suggested it would fight her gastric cancer, and they were right.

[Q]: Paragraph: The state Agriculture Department said in a news release that tests confirmed the presence of the H7 strain of Highly Pathogenic Avian Influenza, or HPAI, at a facility in Lincoln County. The facility alerted the state veterinarian's office on Friday about an increase in chicken deaths. The statement did not name the facility. The facility and about 30 other poultry farms within about a six-mile radius of the site are under quarantine. "Animal health is our top priority," said Dr. Charles Hatcher, the state veterinarian. "With this HPAI detection, we are moving quickly and aggressively to prevent the virus from spreading." The U.S. Department of Agriculture said 73,500 chickens are in the facility's flock. Officials said HPAI poses no risk to the food supply, and no affected chickens entered the food chain. According to the Centers for Disease Control and Prevention, HPAI can cause up to 100 percent mortality in flocks, often within 48 hours. "Many Tennessee families rely on the poultry industry for their livelihoods, and the state is working closely with local, county and federal partners and the poultry industry to control the situation and protect the flocks that are critical to our state's economy," Tennessee Gov. Bill Haslam said. According to the Tennessee Poultry Association, there are more than 1,650 commercial broiler and breeder houses on more than 550 family farms in the state. The state ranks 13th nationally in broiler production and processing with more than 6 million birds per week at five plants. The statement said the most recent U.S. detection of HPAI was in January 2016 in a commercial turkey flock in Indiana. More than 414,000 turkeys and chickens were euthanized to contain the outbreak. In 2015, U.S. poultry producers, primarily in the upper Midwest, lost more than 48 million birds to bird flu. Minnesota, the country's top turkey producer, and Iowa, the top chicken-egg producer, were the hardest-hit states. Claim: Bird flu detected in chicken breeding facility in Tennessee.
[A]:
A commercial chicken breeding facility in south-central Tennessee has been hit by a strain of bird flu, agriculture officials said Sunday.